


Curriculum Vitae

Name	Se Hyun Kim	
Current Position & Affiliation	Associate professor Division of hematology and medical oncology Department of Internal Medicine Seoul National University Bundang Hospital	
Country	Korea	

Educational Background

1997-2003 Yonsei University College of Medicine, Seoul, Korea
 2004-2008 Residency in Medicine, Severance Hospital, Seoul, Korea
 2011-2013 Fellowship in Medical Oncology, Severance Hospital, Seoul, Korea

Professional Experience

2014-2019 Assistant professor, Division of hematology and medical oncology
 Seoul National University Bundang Hospital
 2018-2020 Visiting Scholar at NCI/NIH (Bethesda)
 2019-Present Associate professor, Division of hematology and medical oncology
 Department of Internal Medicine, Seoul National University Bundang Hospital
 Seongnam, Korea

Professional Organizations

Member of KSMO
 Member of KCSG
 Member of ASCO
 Member of AACR

Main Scientific Publications

Kim SH, Ahn S, Suh KJ, Kim YJ, Park SY, Kang E, Kim EK, Kim IA, Chae S, Choi M, Kim JH Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer. *Breast Cancer Res Treat.* 2020 Oct;183(3):697-704. doi: 10.1007/s10549-020-05811-2.

Heo JY, Yoo SH, Suh KJ, Kim SH, Kim YJ, Ock CY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS. Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients. *Sci Rep.* 2021 Jan 28;11(1):2514. doi: 10.1038/s41598-021-81666-x. PMID: 33510255

Kang M, Park C, Kim SH, Yoon SW, Suh KJ, Kim YJ, Ock CY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS Programmed death-ligand 1 expression level as a

14th Annual Meeting of the Korean Society of Medical Oncology & 2021 International Conference | SEP. 2(THU) - 3(FRI), 2021 SEOUL, KOREA
predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Translational Lung Cancer Research, 01 Feb 2021, 10(2):699- 711 DOI: 10.21037/tlcr-20-893 PMID: 33718015
